embalaje : 5mg
Teléfono : +1 850 650 7790
Synonyms: MitoQ10 mesylate, MitoQ mesylate
| Description | Mitoquinone mesylate (MitoQ10 mesylate) is a potent TRAP1 inhibitor (IC50=0.2 μM). Mitoquinone mesylate is an antioxidant that prevents oxidative damage and targets mitochondria of TPP. |
| Targets & IC50 | SARS-CoV-2 Delta variant:1.6 μM, MHV-A59:0.310 μM |
| In vitro | METHODS: MDA-MB-231 (breast cancer cells), MDA-MB-231BR (brain metastatic breast cancer cells), and U87MG (glioma cells) were treated with Mitoquinone mesylate and cell proliferation was monitored using a live cell imaging system. RESULTS: Mitoquinone mesylate inhibited cell proliferation (IC50=0.38 μM). [1] |
| In vivo | METHODS: To investigate the role of Mitoquinone mesylate in acute pancreatitis in mice, mice were treated with Mitoquinone mesylate (10 mg/kg). RESULTS: Treatment with Mitoquinone mesylate significantly reduced pancreatic edema and neutrophil infiltration. Mitoquinone mesylate increased serum amylase in a dose-dependent manner, approximately doubling at higher doses. Mitoquinone mesylate treatment nearly doubled caerulein-induced lung MPO activity at a dose of 10 mg/kg, and serum IL-6 levels were also significantly increased. [2] |
| Synonyms | MitoQ10 mesylate, MitoQ mesylate |
| Molecular Weight | 678.81 |
| Formula | C38H47O7PS |
| Cas No. | 845959-50-4 |
| Smiles | [O-]S(=O)(C)=O.O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4C)C(OC)=C(OC)C4=O |
| Relative Density. | no data available |
| Storage | Store at low temperature Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 240 mg/mL (353.56 mM), Sonication is recommended.  H2O: 10 mg/mL (14.73 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (7.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
